Zura Bio (NASDAQ:ZURA) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Zura Bio (NASDAQ:ZURA) from a strong sell rating to a sell rating in a research report released on Saturday.

Several other equities research analysts have also recently commented on ZURA. William Blair assumed coverage on shares of Zura Bio in a research report on Wednesday, July 8th. They issued an “outperform” rating on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zura Bio in a report on Monday, July 6th. Finally, Wedbush reissued an “outperform” rating and issued a $15.00 price target on shares of Zura Bio in a research note on Wednesday, July 1st. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Zura Bio has an average rating of “Moderate Buy” and a consensus price target of $10.75.

Zura Bio Stock Performance

NASDAQ ZURA opened at $5.52 on Friday. The stock has a market cap of $523.74 million, a price-to-earnings ratio of -5.06 and a beta of -0.02. The business has a 50 day simple moving average of $4.69 and a 200 day simple moving average of $5.39. Zura Bio has a 52-week low of $1.39 and a 52-week high of $7.44.

Zura Bio (NASDAQ:ZURA) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.05). On average, analysts predict that Zura Bio will post -0.76 EPS for the current year.

Institutional Trading of Zura Bio

A number of institutional investors have recently made changes to their positions in ZURA. Suvretta Capital Management LLC boosted its holdings in Zura Bio by 1.7% during the fourth quarter. Suvretta Capital Management LLC now owns 5,567,001 shares of the company’s stock worth $29,171,000 after purchasing an additional 94,110 shares during the last quarter. VR Adviser LLC lifted its position in Zura Bio by 15.4% during the 4th quarter. VR Adviser LLC now owns 5,345,115 shares of the company’s stock worth $28,008,000 after buying an additional 713,899 shares in the last quarter. JPMorgan Chase & Co. lifted its position in Zura Bio by 78.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 4,659,951 shares of the company’s stock worth $4,893,000 after buying an additional 2,052,732 shares in the last quarter. Siren L.L.C. boosted its stake in shares of Zura Bio by 187.3% during the 1st quarter. Siren L.L.C. now owns 3,734,866 shares of the company’s stock worth $22,222,000 after buying an additional 2,434,866 shares during the last quarter. Finally, Commodore Capital LP acquired a new position in shares of Zura Bio during the 1st quarter worth about $19,338,000. Institutional investors own 61.14% of the company’s stock.

About Zura Bio

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.